By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



100 Pine Street
Suite 500
San Francisco  California  94111  U.S.A.
Phone: 415-512-7740 Fax: n/a


Adynxx, located in San Francisco, California, is a clinical-stage pharmaceutical company developing a transformative technology platform addressing pain at its molecular roots – preventing the development of pain following surgery or trauma and resolving established chronic pain syndromes. Adynxx’s unique approach is to modify the course of pain rather than merely manage symptoms.


October 2007


Founder and CSO: Julien Mamet

CEO: Rick Orr

CMO: Donald C. Manning

Key Statistics

Ownership: Private

Web Site: Adynxx


Company News
Adynxx Release: Biotech Announces Closing Of Series B Financing 1/10/2017 6:14:38 AM
Adynxx Completes Patient Enrollment In Phase 2 Dose-Ranging Study Of AYX1 For Prevention Of Post-Surgical Pain 5/14/2015 6:26:23 AM
Adynxx Initiates Phase 2 Dose-Ranging Study Of AYX1, Lead Compound For The Prevention Of Post-Surgical Pain 7/16/2014 9:29:30 AM
Adynxx Completes Patient Enrollment in Phase 2 Clinical Study of Lead Therapeutic for Prevention of Pain, AYX1 9/5/2013 9:34:46 AM
FDA Grants Fast Track Designation to Adynxx Lead Compound AYX1 7/17/2013 8:31:04 AM
Adynxx Enrolls First Patient in Phase 2 Proof-of-Concept Study for AYX1, Lead Compound for the Prevention of Post-Surgical Pain 2/25/2013 11:21:19 AM
Lead Therapeutic Candidate for Treatment of Pain from Adynxx, AYX1, Well-Tolerated in Phase 1 Clinical Study 9/5/2012 10:23:03 AM
Adynxx Completes Enrollment in Phase 1 Clinical Study of Lead Therapeutic for Treatment of Pain, AYX1 8/7/2012 10:38:45 AM